AGENUS INC
No SEC Form 4 filings for $AGEN in the last 30 days.
See all $AGEN insider activity →Benzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
Agenus' unit has entered a second loan modification agreement with Ocean 1181, according to an SEC filing. The agreement is set to take effect on August 12, 2026.
AGENUS INC (AGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001098972 0001098972 2026-08-12 2026-08-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12
Over the past 7 days, alphai's AI scored 3 news stories mentioning AGEN (AGENUS INC). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent AGEN coverage spans corporate actions, market movers and earnings.
Bullish call activity could support AGEN price.
Loan modification terms can change near-term liquidity, covenant headroom, and refinancing risk for Agenus.
The 8-K discloses refinancing terms that extend debt duration and change payment mechanics via stock issuance, affecting dilution and near-term cash needs.
The 8-K is a new, company-specific equity compensation structure that can affect near-term sentiment and option overhang expectations, but it is not a fundamental operating update.
Board expansion and a new director appointment are typically low-to-moderate signal events, with limited direct operational impact.
alphai scores every news story that mentions AGEN with an AI model for sentiment and relevance, and aggregates insider trades from AGENUS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Benzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readAgenus' unit has entered a second loan modification agreement with Ocean 1181, according to an SEC filing. The agreement is set to take effect on August 12, 2026.
1 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001098972 0001098972 2026-08-12 2026-08-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12
4 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001098972 0001098972 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10
2 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001098972 0001098972 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05
2 min readAgenus (AGEN) shares fell about 7% after Q2 results. The company reported Q2 revenue of about $34.5m, while net income swung to a loss of about $0.6m and basic EPS returned to a small loss. Trailing twelve-month profit of $91.8m was driven by a one-off $110.3m gain, raising questions about earnings durability.
5 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001098972 0001098972 2026-08-06 2026-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06
2 min readBiotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.
7 min readAgenus (Nasdaq: AGEN) said three investigator-sponsored BOT+BAL abstracts were accepted for poster presentation at ESMO 2026 (Oct 23-27) in Madrid. The posters cover neoadjuvant dMMR colorectal cancer (NEOASIS), refractory MSS/pMMR metastatic colorectal cancer, and advanced sarcoma. Agenus did not provide new efficacy figures.
3 min readAgenus Inc. (NASDAQ:AGEN) shares fell Tuesday after a record Monday surge of about 95% to 111% amid profit-taking. On Monday, the company reported Phase 1b data for botensilimab plus balstilimab in refractory MSS metastatic colorectal cancer, with median OS 21.2 months. Agenus also announced an $85M private placement plus up to $255M in warrants to fund its Phase 3 ROBBIN trial and shift from BATTMAN. HC Wainwright raised its AGEN price target to $30.
6 min read
